Richmond Pharmacology is delighted to confirm our participation in BIO International Convention 2025 in Boston, the premier global event for biotechnology, attracting innovators and industry leaders from around the world.

With thousands of professionals expected to attend, this year’s convention will emphasize breakthroughs in therapeutic discovery, cutting-edge technologies, and global clinical collaboration.

Representing Richmond Pharmacology at BIO International Convention:

●    Dr. Jörg Täubel, Chief Executive Officer

●    Dr Lisa Campbell, Director of Regulatory Strategy

●    Stephen Wilkinson, Business Development Manager

●    Amina Senoussi, Key Account Executive

Our team is excited to connect with biotech innovators and trial sponsors to explore opportunities in:

●    Gene editing and RNA-based therapies

●    Rare and ultra-rare disease research

●    Innovative regulatory pathways

●    Bridging studies

●    Patient-centric clinical trial delivery

Whether you're advancing a ground breaking therapy or expanding into new markets, we invite you to meet us at Booth 765 in the Exhibit Hall to discover how Richmond Pharmacology can help achieve your clinical development objectives.

For meeting requests or collaboration inquiries, please contact:
📧 s.wilkinson@richmondpharmacology.com

 Learn more about the event

Latest news

Richmond Pharmacology Appoints Dr Daniel Chapple as Commercial Director

July 13, 2026
Richmond Pharmacology, the London-based contract research organisation and global leader in early phase clinical trials, announces the appointment of Dr Daniel Chapple PhD FCIM as Commercial Director.
Read more

Upcoming Event

ESC Congress 2026

28 - 31 August 2026
Richmond Pharmacology is pleased to attend the ESC Congress 2026 in Munich, Germany, on 28 - 31 August 2026.
View event